CYP2C9

The CYP2C family of enzymes is the second most abundant of the CYP enzymes represented in the hepatocyte. The commonest is CYP3A4/5. Correspondingly they are also the second most important enzymes involved in drug metabolism.

There are 4 members of this family, 2C8, 2C9, 2C19 and 2C18, whose genes are all located on chromosome 10. The 2 members of this family that are of greatest importance for us are CYP2C9 and CYP2C10. CYP2C8 came into prominence initially in an association with the cerivastatin induced rhabdomyolysis and later in association with irinotecan metabolism. There has not been a lot of discussions about it lately because of the limited range of substrates linked with it. There is also little known about drug substrates associated with CYP2C18.

CYP2C9, originally known as tolbutamide hydroxylase, has been shown to be involved extensively in the metabolism of many pharmaceuticals. Of topical interest is its involvement with the metabolism with warfarin, particularly the S-isomer.

The Pharmacogenomics Journal (2005) 5, 193–202

The S:R isomeric ration of warfarin concentrations is routinely used as a convenient way of phenotyping the 2C9 activity. The common loss of function genetic variants are the *2 and *3 variants. These variants are much more common among Caucasian populations as compared to East Asians, e.g. Chinese, Japanese and Koreans. In Singapore, the ethnic group which had the highest frequencies of the *2 and *3 variants are the Indians, who had similar frequencies to the Caucasian populations.

CYP2C19 is much more of a preoccupation for us as the *2 and *3 variants are much more common among Chinese than Caucasians. The *2 alleleic variants is particularly common at about 25%. The CYP2C19 was earlier known by the original studied substrate, mephenytoin hydroxylase. The CYP2C19 genetic polymorphism has been discussed largely because if the association of the enzyme with the metabolism of proton pump inhibitors, and lately with the

antiplatelet drug clopidogrel.

Comparison of prasugrel 60 mg and clopidogrel 600 mg loading dose exposure of active metabolite by CYP2C19 genetic classification. Box represents median, 25th, and 75th percentiles and whiskers represent the most extreme values within 1.5 times inter-quartile range of the box. AUC, area under the concentration–time curve; EM, extensive metabolizer; RM, reduced metabolizer.

Eur Heart J (2009) 30 (14): 1744-1752

Clopidogrel - variability in response

Indian Heart Journal. 2008 Nov-Dec; 60(6): 543-7

The use of clopidogrel presents another interesting challenge with respect to the variability in drug response.

Clopidogrel is a a platelet inhibitor, acting through irreversible binding to the P2Y12 purinergic receptor on the platelet membrane; though it is not clopidogrel itself that binds, but the active metabolite. The PK of clopidogrel itself is quite complex. Upon oral administration about 90% of clopidogrel is removed through the action of circulating and hepatic esterases to inactive metabolites. Only about 10-15% gets activated by CYP2C19 and CYP3A4 to the final metabolite that binds to the P2Y12 receptor. As the receptor inactivation is irreversible, the recovery of function is dependent on fresh platelet regeneration from megakaryocytes.

The way clopidogrel produces its action is therefore fraught with all kinds of problems which clearly contributes to the observed variability in therapeutic response. These are potential sources of variability:

a) high first pass and low active metabolite bioavailability

b) variability of CYP3A4 and CYP2C19 activities due to pharmacogenetics and food/drug interactions

c) irreversible binding to receptor

d) temporal delay in onset, as well as in recovery of platelet function

e] variability in rate of platelet recovery.

This extent of variability really points to a crying need for dosages of clopidogrel to be optimized according to some clinical measure of drug response. Unlike the situation with warfarin however, there isn't a universally accepted way of monitoring plate function. Nevertheless, platelet function test is shaping up to become a standard bedside test for this very reason. A recent review by Williams et al (Thromb Haemost 2010; 103: 29–33) is worth a read.

Drug level testing would clearly not be useful as it is not clopidogrel itself but the metabolite that is active. Furthermore the irreversible binding to the platelet purinergic receptor would not allow concentrations of the active metabolite to be useful in predicting the level of platelet inhibition.